
What is claimed is:

1. An aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or a pharmaceutically acceptable salt thereof:



(II)



wherein,

⁼⁼⁼⁼ is a single bond or a double bond;

each of R^1 is identical or different, and is independently deuterium, halogen, substituted or unsubstituted hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted alkyl, or substituted or unsubstituted alkoxy;

or two adjacent R^1 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring; in the heterocarbocyclic ring, the heteroatom(s) is(are) oxygen and/or nitrogen, and the number of the heteroatom(s) is 1 to 4;

R^2 is substituted or unsubstituted alkyl or halogen;

each of R^3 is identical or different, and is independently deuterium, halogen, substituted or unsubstituted alkylthio, substituted or unsubstituted hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,  or , wherein R^{1a} is C_1-C_4 alkyl, or two adjacent R^3 together with the two carbon atoms to which they are attached form a 5- to 7- membered carbocyclic ring or heterocarbocyclic ring; in the heterocarbocyclic ring, the heteroatom(s) is(are) oxygen and/or nitrogen, and the number of the heteroatom(s) is 1

to 4;

the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3, and the substituent(s) in the substituted alkylthio in each of R^3 are one or more selected from halogen, C_{1-4} alkyl, hydroxyl, , C_{1-4} alkoxy, C_{1-4} carboxyl, C_{1-4} ester group and C_{1-4} amide group; when there are more substituents than one, then the substituents are identical or different; R^a and R^b are independently hydrogen, or, substituted or unsubstituted alkyl; in R^a or R^b, the substituent(s) in the substituted alkyl is(are) one or more selected from halogen, C_1-C_4 alkyl, hydroxyl, , C_1-C_4 alkoxy, C_1-C_4 carboxyl, C_1-C_4 ester group and C_1-C_4 amide group; R^{a1} and R^{b1} are independently hydrogen or C_1-C_4 alkyl;



in each of R^1 or R^3, the substituent(s) in the substituted hydroxyl or the substituted amino is(are) one or more selected from C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} carboxyl, C_{1-4} ester group and C_{1-4} amide group;


m1 is 0, 1 or 2;

n is 0, 1, 2 or 3; when ⎓ is a double bond and m1 is 1, then R^1 is located on ortho position of the phenyl;

when ⎓ is a double bond and m1 is 2, then two of R^1 are adjacent, and the two adjacent R^1 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring;

the aromatic vinyl or aromatic ethyl derivative represented by general formula (II) excludes the compound:

 ,  or



2. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in claim 1, wherein,

when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are halogen, then the halogen is F, Cl, Br or I;


and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy, the substituted hydroxyl or the substituted amino in each of R^1 and each of R^3, and the substituent(s) in the substituted alkylthio in each of R^3 are C_1-C_4 alkyl, then the C_1-C_4 alkyl is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;






and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are , and R^a or R^b is halogen substituted alkyl, then the halogen is F, Cl, Br or I;



and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are , and R^a or R^b is C_1-C_4 alkyl, then the C_1-C_4 alkyl is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;


and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are , R^a or R^b is 


substituted alkyl, and R^{a1} or R^{b1} is C_1-C_4 alkyl, then the C_1-C_4 alkyl is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;

and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are , R^a or R^b is C_1-C_4 alkoxy substituted alkyl, then the C_{1-4} alkoxy is methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, isobutoxy or *tert*-butoxy;






and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are , R^a or R^b is C_1-C_4 carboxyl substituted alkyl, then the C_{1-4} carboxyl is , , , , ,  or ;


and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are , and R^a or R^b is C_1-C_4 ester group substituted alkyl, then the C_1-C_4 ester group is , and R^{2a} is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;


and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are , and R^a or R^b is C_1-C_4

amide group substituted alkyl, then the C_1-C_4 amide group is , and R^{1b} is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;

and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy, the substituted hydroxyl or the substituted amino in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are C_1-C_4 alkoxy, then the C_{1-4} alkoxy is methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, isobutoxy or *tert*-butoxy;

and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy, the substituted hydroxyl or the substituted amino in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are C_1-C_4 carboxyl, then the C_{1-4} carboxyl is , , , , ,  or ;

and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy, the substituted hydroxyl or the substituted amino in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are C_1-C_4 ester group, then the C_1-C_4 ester group is , and R^{2a} is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;

and/or, when the substituent(s) in the substituted alkyl in each of R^1, R^2 and each of R^3, the substituent(s) in the substituted alkoxy, the substituted hydroxyl or the substituted amino in each of R^1 and each of R^3 and the substituent(s) in the substituted alkylthio in each of R^3 are C_1-C_4 amide group, then the C_1-C_4 amide group is , and R^{1b} is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl.


3. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in claim 1 or claim 2, wherein,

in each of R^1, R^2 and each of R^3, the halogen is F, Cl, Br or I;

and/or, in each of R^1, R^2 and each of R^3, the substituted or unsubstituted alkyl is substituted or unsubstituted C_1-C_4 alkyl; the substituted or unsubstituted C_1-C_4 alkyl is preferably substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted *n*-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted *n*-butyl, substituted or unsubstituted isobutyl, or, substituted or unsubstituted *tert*-butyl;

and/or, in each of R^1 and each of R^3, the substituted or unsubstituted alkoxy is substituted or unsubstituted C_1-C_4 alkoxy; the substituted or unsubstituted C_1-C_4 alkoxy is preferably substituted or unsubstituted methoxy, substituted or unsubstituted ethoxy, substituted or unsubstituted *n*-propoxy, substituted or unsubstituted isopropoxy, substituted or unsubstituted *n*-butoxy, substituted or unsubstituted isobutoxy, or, substituted or unsubstituted *tert*-butoxy;

and/or, in each of R^3, the substituted or unsubstituted alkylthio is -S-R^s, wherein, R^s is substituted or unsubstituted C_1-C_4 alkyl; the substituted or unsubstituted C_1-C_4 alkyl is preferably substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted *n*-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted *n*-butyl, substituted or unsubstituted isobutyl, or, substituted or unsubstituted *tert*-butyl;

and/or, in each of R^3, in , R^{1a} is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl.4. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in at least one of claims 1 to 3, wherein,

each of R^1 is independently halogen, or, substituted or unsubstituted alkyl; or two

adjacent R^1 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring;

and/or, R^2 is alkyl or halogen;

and/or, each of R^3 is independently halogen, alkylthio or alkoxy; or two adjacent R^3 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring;

and/or, n is 0, 1, 2 or 3;

and/or, m1 is 1 or 2; preferably, m1 is 1.

5. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in claim 4, wherein,

when R^1 is substituted alkyl, the substituent(s) in the substituted alkyl is(are) one or more selected from halogen and ; R^a and R^b are independently hydrogen, or, substituted or unsubstituted alkyl; in R^a or R^b, the substituent(s) in the substituted alkyl is(are) one or more selected from hydroxyl and C_1-C_4 carboxyl;

and/or, when n is 1, then R^3 is halogen, alkylthio or alkoxy; and R^3 is located on ortho, meta or para position of the phenyl;

and/or, when n is 2, then two R^3 are located on ortho and meta positions of the phenyl, and the two R^3 are identical or different; or two R^3 are adjacent, and the two adjacent R^3 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring;


















and/or, when n is 3, then two of R^3 are adjacent, and the two adjacent R^3 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring;


and/or, when m1 is 1, then R^1 is located on ortho position of the phenyl; R^1 located on ortho position of the phenyl is alkyl or alkyl substituted by halogen;

and/or, when m1 is 2, then two of R^1 are adjacent, and the two adjacent R^1 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring.

6. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in claim 5, wherein,

R^1 located on ortho position of the phenyl is $C_{1\text{-}4}$ alkyl or $C_{1\text{-}4}$ alkyl substituted by one or more halogen, such as trifluoromethyl;

and/or, the alkyl substituted by  is C_1-C_4 alkyl substituted by ; the C_1-C_4 alkyl substituted by  is preferably  or , wherein, one of R^a and R^b is H, and the other is alkyl substituted by hydroxyl and/or carboxyl; the C_1-C_4 alkyl substituted by  is more preferably , , ,  or , wherein, the carbon labelled by * is an *S*-configuration chiral carbon, an *R*-configuration chiral carbon or an achiral carbon;  is preferably ;  is preferably ;  is preferably  or ;  is preferably , 

or  .

7. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in at least one of claims 1 to 6, wherein,

each of R^1 is independently substituted or unsubstituted alkyl; or two adjacent R^1 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring; the substituent(s) in the substituted alkyl is(are) one or more selected from halogen and  ; R^a and R^b are independently hydrogen, or, substituted or unsubstituted alkyl; in R^a or R^b, the substituent(s) in the substituted alkyl is(are) one or more selected from hydroxyl and C_1-C_4 carboxyl;

R^2 is alkyl or halogen;


each of R^3 is independently halogen, alkylthio or alkoxy; or two adjacent R^3 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring;










n is 0, 1, 2 or 3; when n is 1, then R^3 is halogen, alkylthio or alkoxy; and R^3 is located on ortho, meta or para position of the phenyl; when n is 2, then two $R^3$are located on ortho and meta positions of the phenyl, wherein, the two R^3 are identical or different; or two R^3 are adjacent, and the two adjacent R^3 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring; when n is 3, then one of R^3 is halogen, the other two R^3 are adjacent, and the two adjacent R^3 together with the two carbon atoms to which they are attached form a 5- to 7- membered heterocarbocyclic ring;













m1 is 1 or 2; when m1 is 1, then R^1 is located on ortho position of the phenyl, R^1 located on ortho position of the phenyl is alkyl or alkyl substituted by halogen; when m1 is 2, then two of R^1 are adjacent, and the two adjacent R^1 together with the two carbon atoms

to which they are attached form a 5- to 7- membered heterocarbocyclic ring.


8. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in at least one of claims 1 to 7, wherein,


is



,

,

,

,

,

,

,

,

or

;

and/or,

is

,

,

,

,

,

,

,

,

,

,

,


,


or

.


9. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in claim 8, wherein,


 can be replaced by .


10. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof, wherein, the aromatic vinyl or aromatic ethyl derivative represented by general formula (II) is:



1



2



3



4



5



6



7



8


9



10


11



12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




32



33



34

11. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in claim 1, wherein,  is replaced by a substituted or unsubstituted heteroaromatic ring; the substituent(s) in the substituted heteroaromatic ring is(are) one or more selected from halogen, $C_{1\text{-}4}$ alkyl, hydroxyl, , $C_{1\text{-}4}$ alkoxy, $C_{1\text{-}4}$ carboxyl, $C_{1\text{-}4}$ ester group and $C_{1\text{-}4}$ amide group; when there are more substituents than one, then the substituents are identical or different; R^a and R^b are independently hydrogen, or, substituted or unsubstituted alkyl; in R^a or R^b, the substituent(s) in the substituted alkyl is(are) one or more selected from halogen, C_1-C_4 alkyl, hydroxyl, , C_1-C_4 alkoxy, C_1-C_4 carboxyl, C_1-C_4 ester group and C_1-C_4 amide group; R^{a1} and R^{b1} are independently hydrogen or C_1-C_4 alkyl;

the heteroaromatic ring is benzoxazole ring, benzopyrazole ring, pyrazine ring, imidazopyrazine ring or pyridine ring.

12. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II)

or the pharmaceutically acceptable salt thereof as defined in claim 11, wherein,

when the substituent(s) in the substituent(s) in the heteroaromatic ring are halogen, then the halogen is F, Cl, Br or I;

and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are C_1-C_4 alkyl, then the C_1-C_4 alkyl is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;







and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are , and R^a or R^b is halogen substituted alkyl, then the halogen is F, Cl, Br or I;


and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are , and R^a or R^b is C_1-C_4 alkyl, then the C_1-C_4 alkyl is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;


and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are , R^a or R^b is  substituted alkyl, and R^{a1} or R^{b1} is C_1-C_4 alkyl, then the C_1-C_4 alkyl is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;

and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are , R^a or R^b is C_1-C_4 alkoxy substituted alkyl, then the C_{1-4} alkoxy is methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, isobutoxy or *tert*-butoxy;







and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are , R^a or R^b is C_1-C_4 carboxyl substituted alkyl, then the C_{1-4} carboxyl is ,


, , , ,  or ;

and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are , and R^a or R^b is C_1-C_4 ester group substituted alkyl, then the C_1-C_4 ester group is , and R^{2a} is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;


and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are , and R^a or R^b is C_1-C_4 amide group substituted alkyl, then the C_1-C_4 amide group is , and R^{1b} is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;

and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are C_1-C_4 alkoxy, then the $C_{1\text{-}4}$ alkoxy is methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, isobutoxy or *tert*-butoxy;


and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are C_1-C_4 carboxyl, then the $C_{1\text{-}4}$ carboxyl is , , , , ,  or ;

and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are C_1-C_4 ester group, then the C_1-C_4 ester group is , and R^{2a} is methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl;


and/or, when the substituent(s) in the substituent(s) in the heteroaromatic ring are C_1-


C_4 amide group, then the C_1-C_4 amide group is , and R^{1b} is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *tert*-butyl.

13. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in claim 11, wherein,



14. The aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in claim 11, wherein, the aromatic vinyl or aromatic ethyl derivative is:






43

and .

15. A method for preparing the aromatic vinyl or aromatic ethyl derivative represented by general formula (II) as defined in at least one of claims 1 to 14, which comprises the following step: conducting a reductive amination reaction of compound (I-a) with




to obtain the compound represented by general formula (II);




（ I-a）　　（ II）

in the general formulae above, the definitions of R^1, R^2, R^3, n, m1, R^a and R^b are as defined in at least one of claims 1 to 14.

16. The method as defined in claim 15, wherein, the method for preparing the compound (I-a) comprises the following step: in a solvent, in the presence of a palladium catalyst, conducting a coupling reaction of compound (II-b) and




to obtain the compound (I-a);







（ II-b）　　（ I-a）

wherein, the definitions of R^1, R^2, R^3, n, m1, R^a and R^b are as defined in claim 15, and X is halogen.


17. A compound represented by formula (I-a):




（ I-a）

wherein, the definitions of R^1, R^2, R^3 and n are as defined in at least one of claims 1 to 14, and m1 is 0, 1 or 2; and  is not ,  or .


18. The compound represented by formula (I-a) as defined in claim 17, which is:




2-a




3-a




4-a




5-a




6-a




7-a




9-a




10-a




11-a




12-a




13-a




14-a




15-a




16-a




18-a




24-a



33-a




35-a




37-a


39-a



40-a




41-a



42-a

or



43-c

.

19. A use of the aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in at least one of claims 1 to 14 in the manufacture of a medicament for preventing, alleviating or treating cancer, infection, autoimmune diseases or related diseases thereof; the cancer is preferably one or more selected from lung cancer, esophageal cancer, stomach cancer, colorectal cancer, liver cancer, nasopharyngeal cancer, brain tumor, breast cancer, cervical cancer, blood cancer and bone cancer.

20. A pharmaceutical composition, which comprises a therapeutically and/or prophylactically effective amount of the aromatic vinyl or aromatic ethyl derivative represented by general formula (II) or the pharmaceutically acceptable salt thereof as defined in at least one of claims 1 to 14, and a pharmaceutically acceptable carrier and/or a diluent.